# Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study

> **NCT06304168** · — · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 6150 (estimated)

## Conditions studied

- Hematopoietic and Lymphatic System Neoplasm
- Malignant Solid Neoplasm

## Interventions

- **OTHER:** Non-Interventional Study

## Key facts

- **NCT ID:** NCT06304168
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-05-13
- **Primary completion:** 2028-05-15
- **Final completion:** 2028-05-15
- **Target enrollment:** 6150 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06304168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06304168, "Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06304168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*